Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies

Grillon, Antoine; Schramm, Frédéric; Kleinberg, Magali; Jehl, F.

doi:10.1371/journal.pone.0156690

Cited by 98 publications

(62 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When we evaluated the time-kill studies with the ET37 concentration of 4 μg/ml, equal to the theoretical plasma peak [41], we observed 6-log decrease at 24 h for strain SG1, SG58, AA12, and AA11 (Figure 9), which are the most susceptible according to their MICs (Table 2). Interestingly, a bactericidal activity was observed with 3.0-log inoculum reduction at 12 h for strains AA2 and TR66, that were categorized as intermediate and TR2 and KK72, that were considered resistant to cipro oxacin (Table 2) ( Figure 9).…”

Section: Et37 E Ect On P Aeruginosa Clinical Strains Susceptibility mentioning

confidence: 98%

Conjugation of LasR Quorum-Sensing Inhibitors with Ciprofloxacin Decreases the Antibiotic Tolerance ofP. aeruginosaClinical Strains

Bortolotti

Trapella

Bragonzi

et al. 2019

Journal of Chemistry

View full text Add to dashboard Cite

Pseudomonas aeruginosa is a Gram-negative bacterium that commonly infects subjects with weakened immune system causing deadly infections above all at pulmonary level. During infection, P. aeruginosa produces a well-organized bacterial structure, called biofilm, activating the quorum-sensing (QS) signaling, a mechanism of gene regulation. In this work, we synthesized already known QS inhibitors (QSi) designed on the scaffold of the N-(3-oxododecanoyl) homoserine lactone (3O-C12-HSL) QS molecule and conjugated them with ciprofloxacin to inhibit P. aeruginosa biofilm formation and increase the antibiotic susceptibility of clinical strains. We identified, for the first time, a QSi conjugated with ciprofloxacin (ET37), that is able to reduce the formation of biofilm and the onset of tolerant clones in P. aeruginosa clinical strains. is compound could have a wide application in clinical setting. e possibility to affect biofilm formation in chronically infected patients, such as patients affected by cystic fibrosis, and to reduce the onset of ciprofloxacin resistance would improve patient healing and allow to decrease antibiotic drug dosage.

show abstract

Section: Et37 E Ect On P Aeruginosa Clinical Strains Susceptibility mentioning

confidence: 98%

Conjugation of LasR Quorum-Sensing Inhibitors with Ciprofloxacin Decreases the Antibiotic Tolerance ofP. aeruginosaClinical Strains

Bortolotti

Trapella

Bragonzi

et al. 2019

Journal of Chemistry

View full text Add to dashboard Cite

show abstract

“…In ELF, the total Cu 2+ concentration returned to physiological values within 18 h of IT administration. In contrast, the CIP concentrations in ELF were still higher than the MIC of CIP against most strains of PA [66]. This indicates that the dose of CIP, and therefore the dose of copper, may be decreased while effective concentrations of CIP may still be obtained.…”

Section: Safetymentioning

confidence: 90%

Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones

Brillault

Tewes

2020

Pharmaceutics

View full text Add to dashboard Cite

Pulmonary drug delivery is a promising strategy to treat lung infectious disease as it allows for a high local drug concentration and low systemic side effects. This is particularly true for low-permeability drugs, such as tobramycin or colistin, that penetrate the lung at a low rate after systemic administration and greatly benefit from lung administration in terms of the local drug concentration. However, for relatively high-permeable drugs, such as fluoroquinolones (FQs), the rate of absorption is so high that the pulmonary administration has no therapeutic advantage compared to systemic or oral administration. Formulation strategies have thus been developed to decrease the absorption rate and increase FQs’ residence time in the lung after inhalation. In the present review, some of these strategies, which generally consist of either decreasing the lung epithelium permeability or decreasing the release rate of FQs into the epithelial lining fluid after lung deposition, are presented in regards to their clinical aspects.

show abstract

“…Fluoroquinolones belong to the family of quinolones, a group of molecules that is widely used as antibiotic because of their large spectrum of bactericidal activity, excellent bioavailability, rapid cellular uptake (Drusano, 1997;Wise and Honeybourne, 1999) and tolerance (Grillon et al, 2016). The bactericidal mechanism of action of fluoroquinolones consists in the inhibition of DNA replication and transcription by interacting with the DNAgyrase complex (Young et al, 2013).…”

Section: Fluoroquinolonesmentioning

confidence: 99%

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Velino

Carella

Adamiano

et al. 2019

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a genetic disease affecting today nearly 70,000 patients worldwide and characterized by a hypersecretion of thick mucus difficult to clear arising from the defective CFTR protein. The overproduction of the mucus secreted in the lungs, along with its altered composition and consistency, results in airway obstruction that makes the lungs susceptible to recurrent and persistent bacterial infections and endobronchial chronic inflammation, which are considered the primary cause of bronchiectasis, respiratory failure, and consequent death of patients. Despite the difficulty of treating the continuous infections caused by pathogens in CF patients, various strategies focused on the symptomatic therapy have been developed during the last few decades, showing significant positive impact on prognosis. Moreover, nowadays, the discovery of CFTR modulators as well as the development of gene therapy have provided new opportunity to treat CF. However, the lack of effective methods for delivery and especially targeted delivery of therapeutics specifically to lung tissues and cells limits the efficiency of the treatments. Nanomedicine represents an extraordinary opportunity for the improvement of current therapies and for the development of innovative treatment options for CF previously considered hard or impossible to treat. Due to the peculiar environment in which the therapies have to operate characterized by several biological barriers (pulmonary tract, mucus, epithelia, bacterial biofilm) the use of nanotechnologies to improve and enhance drug delivery or gene therapies is an extremely promising way to be pursued. The aim of this review is to revise the currently used treatments and to outline the most recent progresses about the use of nanotechnology for the management of CF.

show abstract

Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies

Cited by 98 publications

References 21 publications

Conjugation of LasR Quorum-Sensing Inhibitors with Ciprofloxacin Decreases the Antibiotic Tolerance ofP. aeruginosaClinical Strains

Conjugation of LasR Quorum-Sensing Inhibitors with Ciprofloxacin Decreases the Antibiotic Tolerance ofP. aeruginosaClinical Strains

Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones

Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis

Contact Info

Product

Resources

About